Literature DB >> 20854053

Mortality in COPD: causes, risk factors, and prevention.

Cristine E Berry1, Robert A Wise.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading and increasing cause of death, the extent of which is underestimated as a consequence of underdiagnosis and underreporting on death certificates. Data from large trials, such as the Lung Health Study, Towards a Revolution in COPD Health (TORCH), Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT), European Respiratory Society Study on Chronic Obstructive Pulmonary Disease (EUROSCOP), and Inhaled Steroids in Obstructive Lung Disease (ISOLDE), have shown that the causes of death in patients with mild COPD are predominantly cancer and cardiovascular disease, but as COPD severity increases, deaths due to non-malignant respiratory disease are increasingly common. In practice, mortality of patients with COPD can be predicted by a variety of measures including: forced expiratory volume in one second (FEV(1)), the ratio of inspiratory and total lung capacities, exercise capacity, dyspnea scores, and composite indices such as the body-mass index (B), degree of airflow obstruction (O), degree of functional dyspnea (D), and exercise capacity (E) (BODE) index. Smoking cessation improves survival in COPD patients, and in select patients with advanced disease, oxygen therapy, lung volume reduction surgery, or lung transplantation may also improve survival.

Entities:  

Mesh:

Year:  2010        PMID: 20854053      PMCID: PMC7273182          DOI: 10.3109/15412555.2010.510160

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  59 in total

1.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

2.  Single vs bilateral, sequential lung transplantation for end-stage emphysema: influence of recipient age on survival and secondary end-points.

Authors:  D M Meyer; L E Bennett; R J Novick; J D Hosenpud
Journal:  J Heart Lung Transplant       Date:  2001-09       Impact factor: 10.247

3.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

Authors:  R A Pauwels; C G Löfdahl; L A Laitinen; J P Schouten; D S Postma; N B Pride; S V Ohlsson
Journal:  N Engl J Med       Date:  1999-06-24       Impact factor: 91.245

Review 4.  Undiagnosed airflow obstruction: prevalence and implications.

Authors:  David B Coultas; Douglas W Mapel
Journal:  Curr Opin Pulm Med       Date:  2003-03       Impact factor: 3.155

5.  Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study.

Authors:  D M Mannino; A S Buist; T L Petty; P L Enright; S C Redd
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

6.  Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?

Authors:  S F P Man; L Xing; J E Connett; N R Anthonisen; R A Wise; D P Tashkin; X Zhang; R Vessey; T G Walker; B R Celli; D D Sin
Journal:  Eur Respir J       Date:  2008-09-17       Impact factor: 16.671

7.  C-reactive protein levels and survival in patients with moderate to very severe COPD.

Authors:  Juan P de Torres; Victor Pinto-Plata; Ciro Casanova; Hanna Mullerova; Elizabeth Córdoba-Lanús; Mercedes Muros de Fuentes; Armando Aguirre-Jaime; Bartolome R Celli
Journal:  Chest       Date:  2008-03-13       Impact factor: 9.410

8.  Disease-specific survival benefit of lung transplantation in adults: a national cohort study.

Authors:  A Titman; C A Rogers; R S Bonser; N R Banner; L D Sharples
Journal:  Am J Transplant       Date:  2009-07       Impact factor: 8.086

9.  Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group.

Authors: 
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

10.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.

Authors:  Bartolome Celli; Marc Decramer; Steven Kesten; Dacheng Liu; Sunil Mehra; Donald P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

View more
  53 in total

Review 1.  Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence.

Authors:  Gülmisal Güder; Frans H Rutten
Journal:  Curr Heart Fail Rep       Date:  2014-09

2.  Telomerase mutations in smokers with severe emphysema.

Authors:  Susan E Stanley; Julian J L Chen; Joshua D Podlevsky; Jonathan K Alder; Nadia N Hansel; Rasika A Mathias; Xiaodong Qi; Nicholas M Rafaels; Robert A Wise; Edwin K Silverman; Kathleen C Barnes; Mary Armanios
Journal:  J Clin Invest       Date:  2014-12-22       Impact factor: 14.808

3.  Office-Based Sedation/General Anesthesia for COPD Patients, Part II.

Authors:  Kristin Chino; Steven Ganzberg; Kristopher Mendoza
Journal:  Anesth Prog       Date:  2019

4.  The ability of self-rated health to predict mortality among community-dwelling elderly individuals differs according to the specific cause of death: data from the NEDICES cohort.

Authors:  Mario Fernández-Ruiz; Juan M Guerra-Vales; Rocío Trincado; Rebeca Fernández; María José Medrano; Alberto Villarejo; Julián Benito-León; Félix Bermejo-Pareja
Journal:  Gerontology       Date:  2013-04-18       Impact factor: 5.140

Review 5.  Office-Based Sedation/General Anesthesia for COPD Patients, Part I.

Authors:  Kristin Chino; Steven Ganzberg; Kristopher Mendoza
Journal:  Anesth Prog       Date:  2018

6.  Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort.

Authors:  Raewyn J Hopkins; Fenghai Duan; Caroline Chiles; Erin M Greco; Greg D Gamble; Denise Aberle; Robert P Young
Journal:  Ann Am Thorac Soc       Date:  2017-03

7.  Preventing COPD exacerbations: new options for a crucial and growing problem.

Authors:  Jeffrey L Curtis; Carlos H Martinez
Journal:  Fed Pract       Date:  2014-03

Review 8.  Telomerase and the Genetics of Emphysema Susceptibility. Implications for Pathogenesis Paradigms and Patient Care.

Authors:  Susan E Stanley; Samantha J Merck; Mary Armanios
Journal:  Ann Am Thorac Soc       Date:  2016-12

9.  Evaluation of Bayesian spatio-temporal latent models in small area health data.

Authors:  Jungsoon Choi; Andrew B Lawson; Bo Cai; Md Monir Hossain
Journal:  Environmetrics       Date:  2011-12       Impact factor: 1.900

Review 10.  Autophagy in Pulmonary Diseases.

Authors:  Kiichi Nakahira; Maria Angelica Pabon Porras; Augustine M K Choi
Journal:  Am J Respir Crit Care Med       Date:  2016-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.